Bio-economy news

Subscribe to Bio-economy news feed Bio-economy news
Business Wire - The global leader in news distribution
Updated: 8 min 42 sec ago

Therapure Biopharma Launches Biologics Division as Evolve Biologics™, an Innovative Plasma-Derived Therapeutics Company

Fri, 23/03/2018 - 20:00

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)

Fri, 23/03/2018 - 09:00
CORK, Ireland--(BUSINESS WIRE)--Janssen Announces Positive CHMP Opinion for JULUCA▼ (dolutegravir/rilpivirine)

Triumvira Immunologics to Present at the 25th BioCentury Future Leaders Conference

Thu, 22/03/2018 - 10:00
TORONTO & AUSTIN, Texas--(BUSINESS WIRE)--Triumvira Immunologics, a biopharmaceutical company developing a platform engineering T cells to attack cancers, will be presenting at Future Leaders.

Facedrive signs DependableIT and DynaLync to Manage Business Process and IT Platform Development

Thu, 22/03/2018 - 09:00
TORONTO--(BUSINESS WIRE)--#Investment--Facedrive Inc. (“Facedrive”), a growing peer-to-peer ridesharing network, selects DependableIT (“DIT”), an integrated call centre solution provider, to manage support processes and client service with customers and drivers. Facedrive Inc. also selected DynaLync, an enterprise level IT solutions and staffing firm, to lead technology infrastructure development. Chairman of Facedrive, Sayan Navaratnam, stated “DependableIT leadership in customized call centre solutions, p

Takeda Announces Publication of Final Data from ICLUSIG® (ponatinib) Pivotal Phase 2 PACE Trial in Blood

Thu, 22/03/2018 - 08:00
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that final data from the pivotal Phase 2 PACE clinical trial of ICLUSIG (ponatinib) in refractory chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) were published in Blood. The manuscript is available online today and will be included in a future print edition of Blood. The final five-year results support ICLUSIG as an effect

SemaThera Announces a $2MUS Financing and a Licensing Deal for China and Japan

Wed, 21/03/2018 - 12:00
MONTREAL--(BUSINESS WIRE)--#amorchem--SemaThera Inc announces today the closing of a $2MUS co-investment from Senju Pharmaceutical Co., Ltd. and AmorChem L.P. for the development of its lead candidate, ST-102, in preparation for a clinical trial application in diabetic macular edema (DME). As part of this financing, SemaThera also signed an exclusive option of license with Senju. Under the terms of the agreement, Senju acquired the option rights to exclusively develop and market SemaThera’s ST-102 in Chin

Enigma Biomedical Group and Yale Sign Memorandum of Understanding to License Novel Investigational Synaptic Density Imaging Biomarker Technology

Wed, 21/03/2018 - 09:00
TORONTO--(BUSINESS WIRE)--Enigma Biomedical Group (EBG) today announced execution of a Memorandum of Understanding to license Yale’s Synaptic Density Imaging (SDI) biomarker technology platform. With this license, EBG will be responsible for the global development and commercialization of Yale’s early stage investigational imaging agents using Positron Emission Tomography (PET) to assess neurodegeneration. SDI promises to provide an important new tool in understanding neurodegenerative diseases

Bioasis Appoints Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE as Chair of the Board of Directors

Wed, 21/03/2018 - 09:00
VANCOUVER, British Columbia & GUILFORD, Conn.--(BUSINESS WIRE)--$BIOAF #BBB--Bioasis appoints Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE as chair of the board of directors.

Acerus Reports Fourth Quarter and Full Year 2017 Financial Results

Wed, 21/03/2018 - 07:00
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP) today reported its financial results for the three and twelve-month period ended December 31, 2017. Unless otherwise noted, all amounts are in U.S. dollars. The Company continued to execute on its plan to expand the global reach of Natesto® by signing four additional commercial partnership agreements with medac Gesellschaft fϋr Klinische Spezialprӓparate mbH (“medac”) for 15 countries in Europe,

Morinaga Milk's New Probiotic Strain, Bifidobacterium breve A1, May Prevent Onset of Alzheimer's Disease

Tue, 20/03/2018 - 15:00
TOKYO--(BUSINESS WIRE)--Morinaga Milk released a new study showing its new probiotic strain Bifidobacterium breve A1 has the preventive effects to Alzheimer's disease.

Antibe Therapeutics Announces Successful Phase 2B Gastrointestinal Safety Study for Lead Pain Drug, ATB-346

Tue, 20/03/2018 - 09:00
TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its lead drug, ATB-346, met its primary endpoint in the Phase 2B gastrointestinal (“GI”) safety study. The double-blind study was conducted in 244 healthy volunteers and was designed to demonstrate the superiority of ATB-346 in GI safety compared to naproxen, the most prescribed nonsteroidal anti-inflammatory drug (“NSAID”) in the USA. Subjects on ATB-346 exhibite

Kalytera Initiates Program to Develop a Novel Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain

Tue, 20/03/2018 - 08:00
SAN FRANCISCO & TEL AVIV, Israel--(BUSINESS WIRE)--Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has begun development of a novel cannabinoid-based compound for the treatment of acute and chronic pain. Patents for this compound have been filed in the U.S. and other jurisdictions, and Kalytera has obtained an exclusive, worldwide license for this compound from Beetlebung Pharma, Ltd., an Israeli-based pharmaceutical discove

Xytex Standards Support Scientific Breakthrough Regarding Stressed Out Sperm

Mon, 19/03/2018 - 13:00
ATLANTA--(BUSINESS WIRE)--Xytex sperm standards support scientific breakthrough regarding stressed out sperm.

CanniMed Therapeutics Inc. Announces First Quarter Results

Mon, 19/03/2018 - 08:00
SASKATOON, Saskatchewan--(BUSINESS WIRE)--CanniMed Therapeutics Inc. Announces First Quarter Results

CanniMed Therapeutics Inc. Announces Quarterly Results Release Date

Fri, 16/03/2018 - 08:00
SASKATOON, Saskatchewan--(BUSINESS WIRE)--CanniMed Therapeutics Inc. Announces Quarterly Results Release Date

Changes to CanniMed Therapeutics Board Following Share Take-Up by Aurora Cannabis

Thu, 15/03/2018 - 19:00
EDMONTON, Alberta & SASKATOON, Saskatchewan--(BUSINESS WIRE)--Changes to CanniMed Therapeutics Board Following Share Take-Up by Aurora Cannabis

Aurinia Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights

Thu, 15/03/2018 - 17:00
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights

Biogen to Present at the 2018 Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting

Thu, 15/03/2018 - 09:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (Nasdaq: BIIB) will present data from its portfolio of investigational therapies for people with neurodegenerative diseases at the Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting in Torino, Italy (March 15-18, 2018). AAT-AD/PD is a new joint meeting between the International Geneva/Springfield Symposium on Advances in Alzheimer’s Therapy and AD/PD™. Alessandro Padovani M.D., Ph.D., professor of neurology and director of the I

Ferring Announces Positive Outcome of European Decentralised Procedure (DCP) for Testavan®, a Treatment for Men with Hypogonadism

Thu, 15/03/2018 - 03:00
SAINT PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the positive outcome of the European Decentralised Procedure (DCP) for Testavan® (transdermal testosterone gel 2%), a testosterone replacement therapy for adult male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests. The Netherlands acted as Reference Member State (RMS) on behalf of all 31 European Economic Areas (EEA) countries.1 “Men suffering from hypogonad

Acerus to Report 2017 Financial Results and Host Investor Call

Wed, 14/03/2018 - 18:00
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) will announce financial results for the three and twelve month periods ending December 31, 2017 on Wednesday, March 21, 2018 before market opens. The company will host a conference call on Wednesday, March 21, 2018 at 8:30 a.m. Eastern Time. To access the call live, please dial 416-340-2216 or 1-866-225-2055. Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays. A replay of the conference cal